{"hands_on_practices": [{"introduction": "When medical harm occurs, a core function of the legal system is to provide compensation to the injured party. However, the principles governing how damages are calculated can differ profoundly across jurisdictions, leading to vastly different outcomes for similar injuries. This exercise provides a practical application of comparative tort law, challenging you to quantify the recoverable damages for a medical error under two distinct legal frameworks: California's, with its specific rules on non-economic damage caps and collateral sources, and Germany's, which reflects a different balance influenced by its social insurance system. By performing these calculations, you will gain a concrete understanding of how abstract legal doctrines translate into tangible financial results for patients. [@problem_id:4475972]", "problem": "A patient suffers a surgical error resulting in extended hospitalization, long-term rehabilitation, and loss of earnings. You are asked to compare total damages recoverable by the patient in California versus Germany by applying core tort principles and jurisdiction-specific rules. Use the following scenario and assumptions.\n\nFundamental base to be used in your reasoning:\n- The full compensation principle requires that total recoverable damages equal the sum of economic losses and non-economic losses, subject to jurisdictional limits.\n- The mitigation of damages doctrine requires reducing recoverable losses by avoidable consequences the plaintiff unreasonably failed to prevent.\n- Social insurance offsets and collateral source rules vary by jurisdiction and affect whether amounts paid or payable by social insurers reduce recoverable damages.\n- Non-economic damages may be subject to statutory caps depending on jurisdiction.\n\nScenario inputs:\n- Past medical expenses: total hospital and surgical charges of $\\$600{,}000$. Statutory health insurance has paid $\\$420{,}000$, negotiated write-offs are $\\$150{,}000$, and the patient’s out-of-pocket payments total $\\$30{,}000$.\n- Future medical and rehabilitation over $5$ years are estimated at $\\$350{,}000$ in total services, with social insurance expected to cover $\\$210{,}000$. Assume the patient’s reasonable mitigation (adhering to prescribed therapy) would have reduced total future medical services by $20\\%$, and insurer coverage would have decreased proportionally by $20\\%$ as well. The patient did not mitigate.\n- Lost earnings: gross lost earnings over $2$ years equal $\\$260{,}000$. Statutory sickness benefits paid to the patient total $\\$120{,}000$, and employer wage continuation for the initial period is $\\$10{,}000$. Assume reasonable mitigation (returning to part-time work) would have reduced gross lost earnings by $25\\%$, and public and employer benefits would have decreased proportionally by $25\\%$ as well. The patient did not mitigate.\n- Non-economic losses (pain and suffering) are assessed at $\\$600{,}000$.\n\nJurisdictional rules to apply:\n- California (Medical malpractice, claim arising in calendar year $2023$): Assume the Medical Injury Compensation Reform Act (MICRA) non-economic damages cap applies at $\\$350{,}000$ for non-death cases in $2023$, and that under California Civil Code section $3333.1$, amounts paid or payable by social insurance and employer wage continuation are admissible and used by the court to reduce recoverable economic damages, with no subrogation by collateral sources; future social insurance benefits are reasonably certain and treated analogously.\n- Germany: Assume no statutory cap on non-economic damages (Schmerzensgeld). Assume social insurance and employer continuation benefits eliminate duplicate recovery for the plaintiff via recourse or setoff, so the plaintiff’s recoverable economic damages exclude amounts already covered or payable by social insurance and employer continuation. Mitigation of damages reduces recoverable economic losses as in general tort principles.\n\nTask:\n- Compute total recoverable damages in each jurisdiction by combining economic and non-economic components, applying mitigation and offsets as specified.\n- Then compute the net difference defined as “Germany total minus California total.”\n- Express your final answer in United States Dollars (USD). Round your answer to four significant figures. Do not include units in the final boxed answer.", "solution": "The problem is assessed to be valid. It is a well-posed, self-contained, and objective problem based on a set of clearly defined rules for quantitative legal analysis. The premises are consistent and sufficient for reaching a unique solution. The following is a complete and reasoned solution.\n\nThe objective is to compute the total recoverable damages for a patient in California and Germany under a specified medical malpractice scenario and then to calculate the difference between the two totals. The calculation is segmented into economic and non-economic damages for each jurisdiction, applying the given principles of mitigation and collateral source offsets.\n\n**1. Calculation of Total Recoverable Damages in California**\n\nTotal damages are the sum of recoverable economic and non-economic losses.\n\n**1.1. Economic Damages (California)**\n\nUnder California Civil Code section $3333.1$, amounts paid or payable by collateral sources (social insurance, employer benefits) are used to reduce the recoverable economic damages. The doctrine of mitigation of damages also applies, reducing recovery by the amount of loss that could have been reasonably avoided.\n\n*   **Past Medical Expenses:**\n    The total billed amount for past medical services is $\\$600000$. Of this, statutory health insurance paid $\\$420000$, negotiated write-offs were $\\$150000$, and the patient paid $\\$30000$ out-of-pocket. The patient's incurred loss is the sum of payments made by all parties, which is $\\$420000 + \\$30000 = \\$450000$. The write-off of $\\$150000$ is not a loss.\n    According to the specified rules for California, the insurance payment of $\\$420000$ is offset.\n    $$ \\text{Recoverable Past Medical} = \\text{Patient's Out-of-Pocket Payment} = \\$30000 $$\n\n*   **Future Medical Expenses:**\n    The total estimated cost is $\\$350000$. The patient failed to mitigate damages, which would have reduced this cost by $20\\%$. The avoidable loss is not recoverable.\n    $$ \\text{Avoidable Loss} = 0.20 \\times \\$350000 = \\$70000 $$\n    The recoverable damage calculation is based on the mitigated cost:\n    $$ \\text{Mitigated Future Medical Cost} = \\$350000 - \\$70000 = \\$280000 $$\n    Social insurance was projected to cover $\\$210000$ of the original $\\$350000$ cost. With mitigation, this coverage would decrease proportionally by $20\\%$.\n    $$ \\text{Mitigated Insurance Coverage} = \\$210000 \\times (1 - 0.20) = \\$168000 $$\n    This amount is offset. The recoverable amount is the patient's net loss after mitigation and offsets.\n    $$ \\text{Recoverable Future Medical} = \\text{Mitigated Cost} - \\text{Mitigated Coverage} = \\$280000 - \\$168000 = \\$112000 $$\n\n*   **Lost Earnings:**\n    The gross lost earnings are $\\$260000$. The patient failed to mitigate, which would have reduced this loss by $25\\%$.\n    $$ \\text{Avoidable Loss} = 0.25 \\times \\$260000 = \\$65000 $$\n    The recoverable damage calculation is based on the mitigated loss:\n    $$ \\text{Mitigated Lost Earnings} = \\$260000 - \\$65000 = \\$195000 $$\n    Collateral source benefits (statutory sickness and employer wage continuation) totaled $\\$120000 + \\$10000 = \\$130000$. With mitigation, these benefits would have decreased proportionally by $25\\%$.\n    $$ \\text{Mitigated Benefits} = \\$130000 \\times (1 - 0.25) = \\$97500 $$\n    These benefits are offset. The recoverable amount is the net loss after mitigation and offsets.\n    $$ \\text{Recoverable Lost Earnings} = \\text{Mitigated Loss} - \\text{Mitigated Benefits} = \\$195000 - \\$97500 = \\$97500 $$\n\n*   **Total Economic Damages (California):**\n    $$ D_{\\text{econ, CA}} = \\$30000 + \\$112000 + \\$97500 = \\$239500 $$\n\n**1.2. Non-Economic Damages (California)**\n\nThe non-economic losses (pain and suffering) are assessed at $\\$600000$. However, the problem states that the Medical Injury Compensation Reform Act (MICRA) cap for non-death cases in $2023$ applies, which is $\\$350000$.\n$$ D_{\\text{non-econ, CA}} = \\min(\\$600000, \\$350000) = \\$350000 $$\n\n**1.3. Total Recoverable Damages (California)**\n$$ D_{\\text{total, CA}} = D_{\\text{econ, CA}} + D_{\\text{non-econ, CA}} = \\$239500 + \\$350000 = \\$589500 $$\n\n**2. Calculation of Total Recoverable Damages in Germany**\n\nTotal damages are the sum of recoverable economic and non-economic losses.\n\n**2.1. Economic Damages (Germany)**\n\nThe German rule specifies that recoverable economic damages exclude amounts covered or payable by social insurance and employer continuation. The principle of mitigation of damages also applies. This leads to a calculation of the plaintiff's net loss on a mitigated basis.\n\n*   **Past Medical Expenses:**\n    The patient's out-of-pocket payment is their net loss.\n    $$ \\text{Recoverable Past Medical} = \\$30000 $$\n\n*   **Future Medical Expenses:**\n    The calculation is based on the mitigated net loss. As calculated previously, the mitigated cost is $\\$280000$, and the mitigated insurance coverage is $\\$168000$. The recoverable net loss is the difference.\n    $$ \\text{Recoverable Future Medical} = \\$280000 - \\$168000 = \\$112000 $$\n\n*   **Lost Earnings:**\n    The calculation is based on the mitigated net loss. As calculated previously, the mitigated gross loss is $\\$195000$, and the mitigated collateral benefits are $\\$97500$. The recoverable net loss is the difference.\n    $$ \\text{Recoverable Lost Earnings} = \\$195000 - \\$97500 = \\$97500 $$\n\n*   **Total Economic Damages (Germany):**\n    The calculation for economic damages under Germany's specified rules is identical to California's, as both effectively award the plaintiff their net, mitigated economic loss.\n    $$ D_{\\text{econ, DE}} = \\$30000 + \\$112000 + \\$97500 = \\$239500 $$\n\n**2.2. Non-Economic Damages (Germany)**\n\nThe non-economic losses (Schmerzensgeld) are assessed at $\\$600000$. The rule for Germany specifies no statutory cap.\n$$ D_{\\text{non-econ, DE}} = \\$600000 $$\n\n**2.3. Total Recoverable Damages (Germany)**\n$$ D_{\\text{total, DE}} = D_{\\text{econ, DE}} + D_{\\text{non-econ, DE}} = \\$239500 + \\$600000 = \\$839500 $$\n\n**3. Net Difference in Total Recoverable Damages**\n\nThe final task is to compute the net difference, defined as the total damages in Germany minus the total damages in California.\n\n$$ \\text{Difference} = D_{\\text{total, DE}} - D_{\\text{total, CA}} = \\$839500 - \\$589500 = \\$250000 $$\n\nThe problem requires rounding the answer to four significant figures. The exact answer is $\\$250000$. To express this with four significant figures, it is written as $2.500 \\times 10^5$.", "answer": "$$\\boxed{2.500 \\times 10^{5}}$$", "id": "4475972"}, {"introduction": "Moving from individual compensation to systemic policy, we must ask how healthcare systems decide whether to fund new, often expensive, medical technologies. This is the domain of Health Technology Assessment (HTA), a critical field where law, ethics, and economics intersect to shape patient access to innovation. This practice puts you in the role of a health economist, tasked with evaluating a new oncology drug using the foundational tool of cost-utility analysis. You will calculate the Incremental Cost-Effectiveness Ratio (ICER), a key metric that quantifies the \"value for money\" of a new treatment, and then interpret this result within the contrasting reimbursement frameworks of the United Kingdom and Germany. [@problem_id:4475895]", "problem": "A pharmaceutical company seeks market access in the United Kingdom (UK) and Germany for a new oncology drug, OncoX. You are tasked with conducting a Health Technology Assessment (HTA) grounded in the definition of cost-utility analysis, where clinical benefit is measured as quality-adjusted life years (QALYs), and economic value is assessed by comparing the discounted incremental costs and the discounted incremental QALYs between the new drug and standard care. Assume a cohort-based analysis over a $3$-year horizon with end-of-year discounting at rate $r = 0.035$ per annum for both costs and QALYs; use the end-of-year discount factor $1/(1+r)^{t}$ for year $t \\in \\{1,2,3\\}$. Use the following trial-based inputs, which already incorporate survival and health-state utilities into annual QALYs per patient.\n\n- Annual undiscounted QALYs per patient:\n  - OncoX: year $1$: $0.70$, year $2$: $0.65$, year $3$: $0.25$.\n  - Standard care: year $1$: $0.60$, year $2$: $0.45$, year $3$: $0.10$.\n- Annual undiscounted costs per patient (British pounds):\n  - OncoX drug acquisition and administration: year $1$: $45{,}000$, year $2$: $30{,}000$, year $3$: $0$.\n  - Standard care drug acquisition and administration: year $1$: $8{,}000$, year $2$: $6{,}000$, year $3$: $0$.\n  - Adverse event management (incremental to each arm): OncoX year $1$: $2{,}000$, Standard care year $1$: $1{,}000$, and $0$ thereafter in both arms.\n  - Routine monitoring (common to both arms): $1{,}200$ per year in each of years $1$–$3$.\n\nTasks:\n- Starting from the foundational definition that the incremental analysis compares the difference in present value costs to the difference in present value QALYs, compute the discounted incremental cost and the discounted incremental QALYs of OncoX versus standard care over $3$ years, then compute the ratio of these two quantities.\n- Interpret this ratio as the Incremental Cost-Effectiveness Ratio (ICER) in British pounds per QALY.\n- Briefly assess, in light of high-level legal-institutional criteria, how such an ICER would be viewed under the National Institute for Health and Care Excellence (NICE) approach in the United Kingdom (UK), where routine commissioning commonly references a benchmark range of $20{,}000$ to $30{,}000$ British pounds per QALY, and under Germany’s post-Act on the Reform of the Market for Medicinal Products (AMNOG) framework led by the Institute for Quality and Efficiency in Health Care (IQWiG) and the Federal Joint Committee (G-BA), which relies on added-benefit assessment and an efficiency frontier rather than a fixed ICER threshold.\n\nAnswer specification:\n- Compute the ICER and express it in British pounds per QALY.\n- Round your ICER to four significant figures.\n- Your final submitted answer must be a single real number only (no units, no words).", "solution": "The problem requires a cost-utility analysis of a new drug, OncoX, against standard care, culminating in the calculation of the Incremental Cost-Effectiveness Ratio (ICER). The ICER is defined as the ratio of the incremental cost of an intervention to its incremental health benefit, where the benefit is measured in Quality-Adjusted Life Years (QALYs).\n\nThe foundational formula for the ICER is:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta Q} = \\frac{C_{\\text{OncoX}}^{\\text{disc}} - C_{\\text{Standard}}^{\\text{disc}}}{Q_{\\text{OncoX}}^{\\text{disc}} - Q_{\\text{Standard}}^{\\text{disc}}}\n$$\nwhere $C_X^{\\text{disc}}$ and $Q_X^{\\text{disc}}$ represent the total discounted costs and total discounted QALYs for a given therapy $X$, respectively, over the specified time horizon of $T=3$ years.\n\nThe analysis uses an end-of-year discounting convention with an annual discount rate of $r = 0.035$. The discount factor for a cash flow or QALY in year $t$ is given by $d_t = (1+r)^{-t}$.\n\nFirst, we calculate the total discounted incremental QALYs, $\\Delta Q$. Let $Q_{O,t}$ and $Q_{S,t}$ be the undiscounted QALYs for OncoX and standard care in year $t$, respectively.\nThe total discounted incremental QALY gain is:\n$$\n\\Delta Q = \\sum_{t=1}^{3} \\frac{Q_{O,t} - Q_{S,t}}{(1+r)^{t}}\n$$\nSubstituting the given values:\n- Year $1$: $\\Delta Q_1 = 0.70 - 0.60 = 0.10$\n- Year $2$: $\\Delta Q_2 = 0.65 - 0.45 = 0.20$\n- Year $3$: $\\Delta Q_3 = 0.25 - 0.10 = 0.15$\n\n$$\n\\Delta Q = \\frac{0.10}{(1+0.035)^{1}} + \\frac{0.20}{(1+0.035)^{2}} + \\frac{0.15}{(1+0.035)^{3}}\n$$\n$$\n\\Delta Q \\approx 0.10 \\times (0.96618357) + 0.20 \\times (0.93351070) + 0.15 \\times (0.90194271)\n$$\n$$\n\\Delta Q \\approx 0.09661836 + 0.18670214 + 0.13529141 \\approx 0.41861191\n$$\n\nNext, we calculate the total discounted incremental cost, $\\Delta C$. Let $C_{O,t}$ and $C_{S,t}$ be the total undiscounted costs for OncoX and standard care in year $t$. The incremental cost calculation can exclude costs that are common to both arms, as they cancel out. The routine monitoring cost of $1{,}200$ pounds per year is common to both arms and is thus irrelevant to the incremental analysis.\n\nLet's define the relevant annual costs for each arm:\n- OncoX: $C_{O,t} = C_{O, \\text{drug}, t} + C_{O, \\text{AE}, t}$\n- Standard Care: $C_{S,t} = C_{S, \\text{drug}, t} + C_{S, \\text{AE}, t}$\n\nThe annual incremental costs are:\n- Year $1$: $\\Delta C_1 = (45{,}000 + 2{,}000) - (8{,}000 + 1{,}000) = 47{,}000 - 9{,}000 = 38{,}000$ pounds.\n- Year $2$: $\\Delta C_2 = (30{,}000 + 0) - (6{,}000 + 0) = 30{,}000 - 6{,}000 = 24{,}000$ pounds.\n- Year $3$: $\\Delta C_3 = (0 + 0) - (0 + 0) = 0$ pounds.\n\nThe total discounted incremental cost is:\n$$\n\\Delta C = \\sum_{t=1}^{3} \\frac{\\Delta C_t}{(1+r)^{t}} = \\frac{38{,}000}{(1+0.035)^{1}} + \\frac{24{,}000}{(1+0.035)^{2}} + \\frac{0}{(1+0.035)^{3}}\n$$\n$$\n\\Delta C \\approx 38{,}000 \\times (0.96618357) + 24{,}000 \\times (0.93351070) + 0\n$$\n$$\n\\Delta C \\approx 36{,}714.9757 + 22{,}404.2568 \\approx 59{,}119.2325 \\text{ pounds}.\n$$\n\nNow, we compute the ICER by taking the ratio of the incremental cost to the incremental QALYs.\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta Q} \\approx \\frac{59{,}119.2325}{0.41861191} \\approx 141{,}226.75 \\text{ pounds per QALY}.\n$$\nThe problem asks for the result to be rounded to four significant figures.\n$$\n\\text{ICER} \\approx 141{,}200 \\text{ pounds per QALY}.\n$$\n\nFinally, a brief assessment of this result in the context of the UK and German HTA systems is required.\n\nIn the United Kingdom, NICE generally considers interventions with an ICER below a threshold range of $20{,}000$ to $30{,}000$ pounds per QALY to be cost-effective. The calculated ICER of approximately $141{,}200$ pounds per QALY is substantially above this range. While there are special considerations, such as an \"end-of-life\" modifier or the \"highly specialised technologies\" pathway, that can allow for higher ICERs (typically up to $50{,}000$ pounds per QALY, and in rare cases higher), this drug's ICER is still nearly three times that higher threshold. Therefore, under the NICE framework, OncoX would almost certainly not be recommended for routine commissioning on the National Health Service (NHS) at its current price. A significant price reduction would be necessary.\n\nIn Germany, the AMNOG process, governed by the G-BA and informed by IQWiG's assessments, does not use an explicit ICER threshold. The primary step is the determination of the \"added benefit\" (Zusatznutzen) of the new drug compared to the standard of care. If an added benefit is established, the G-BA negotiates a reimbursement price with the manufacturer. This price is benchmarked against existing therapies for the same indication, forming an \"efficiency frontier\". A drug with a very high incremental cost, as is the case for OncoX, would need to demonstrate a \"major\" or \"considerable\" added benefit to justify a high price. Even then, the price would be subject to intense negotiation to ensure it is proportional to the proven benefit. An ICER of this magnitude would be seen as evidence of a poor relationship between cost and benefit, leading to significant pressure for a price reduction. The German system focuses on what is an appropriate price for the quantum of benefit delivered, rather than a cost-per-QALY metric.\n\nThe numerical answer required is the ICER value rounded to four significant figures.\n$$\n141{,}226.75 \\rightarrow 141{,}200\n$$", "answer": "$$\\boxed{141200}$$", "id": "4475895"}, {"introduction": "In an increasingly interconnected world, a medical dispute may have ties to multiple countries, presenting a strategic choice of where to file a lawsuit—a practice known as \"forum shopping.\" This decision is not merely about finding the court that might award the highest damages; it involves a complex calculation of risks, costs, and the ultimate likelihood of actually collecting a judgment. This final exercise elevates your analysis to the level of legal strategy, asking you to derive and apply a decision model to optimize the expected net recovery from litigation. By comparing three hypothetical jurisdictions, you will learn to quantify the crucial trade-offs between the probability of winning, potential damage awards, litigation costs, and the critical factor of cross-border judgment enforceability. [@problem_id:4475886]", "problem": "A claimant in a cross-border medical malpractice dispute must decide where to file suit among three candidate jurisdictions. The claimant seeks to maximize expected net recovery, denoted by $E[R]$, taking into account that any judgment obtained must be recognized and enforced abroad. In comparative medical law, forum shopping involves selecting the jurisdiction whose legal process and outcomes yield the greatest expected net recovery, factoring in the likelihood that a judgment is enforceable and the costs of litigating. In this model, the following core definitions apply: (i) expected value is the probability-weighted average of outcomes; (ii) enforcement probability $p$ is the probability that a final judgment rendered in a selected jurisdiction will be recognized and satisfied across borders; and (iii) litigation cost $C$ is the claimant’s expected total cost of pursuing the case in that jurisdiction, assumed to be known ex ante.\n\nBegin from these definitions and derive a decision rule that determines, for any jurisdiction with enforcement probability $p$, litigation cost $C$, probability of prevailing $q$, and typical judgment magnitude if successful $D$, how to choose the forum that optimizes $E[R]$.\n\nThen, apply your decision rule to the following three jurisdictions:\n\n- Jurisdiction $\\mathrm{A}$ (a Member State of the European Union (EU) with strong intra-EU judgment recognition): $p_{\\mathrm{A}} = 0.92$, $q_{\\mathrm{A}} = 0.40$, $D_{\\mathrm{A}} = 2.4$ (million United States dollars (USD)), $C_{\\mathrm{A}} = 0.60$ (million USD).\n- Jurisdiction $\\mathrm{B}$ (a country that has acceded to the Hague Convention on the Recognition and Enforcement of Foreign Judgments in Civil or Commercial Matters (Hague Judgments Convention)): $p_{\\mathrm{B}} = 0.78$, $q_{\\mathrm{B}} = 0.50$, $D_{\\mathrm{B}} = 1.8$ (million USD), $C_{\\mathrm{B}} = 0.40$ (million USD).\n- Jurisdiction $\\mathrm{C}$ (a non-party to multilateral recognition instruments, relying on limited bilateral comity): $p_{\\mathrm{C}} = 0.40$, $q_{\\mathrm{C}} = 0.55$, $D_{\\mathrm{C}} = 3.5$ (million USD), $C_{\\mathrm{C}} = 0.90$ (million USD).\n\nUse your derived decision rule to compute the expected net recovery for each jurisdiction and identify the optimal forum. Then, report the optimal expected net recovery value. Round your final answer to four significant figures and express the value in million United States dollars (USD).", "solution": "The objective is to construct a principled decision rule from first principles of expected value and legal recognition. In cross-border litigation, a claimant’s monetary outcome depends on two stages: prevailing on the merits in the chosen forum and successfully enforcing the judgment internationally. The fundamental expected value principle states that the expected value of a random payoff equals the sum of outcome magnitudes weighted by their probabilities. Here, the relevant monetary outcome, if the claimant prevails and the judgment is enforced, is the judgment magnitude, and the relevant probabilities are the probability of prevailing and the probability of enforcement.\n\nLet a candidate jurisdiction be indexed by $i \\in \\{\\mathrm{A}, \\mathrm{B}, \\mathrm{C}\\}$. The probability of prevailing is $q_{i}$, the magnitude of the judgment conditional on prevailing is $D_{i}$, and the probability that the judgment is recognized and enforced abroad is $p_{i}$. Litigation cost $C_{i}$ is a deterministic outlay borne by the claimant for forum $i$. The expected judgment value before enforcement is the expected value of the conditional payoff:\n$$\nE[J_{i}] = q_{i} \\cdot D_{i}.\n$$\nBecause recognition and enforcement are necessary to realize the monetary judgment in a cross-border setting, the expected collected judgment is the enforcement probability times the expected judgment:\n$$\nE[\\text{Collected } J_{i}] = p_{i} \\cdot E[J_{i}] = p_{i} \\cdot q_{i} \\cdot D_{i}.\n$$\nExpected net recovery is the expected collected judgment less litigation cost:\n$$\nE[R_{i}] = p_{i} \\cdot q_{i} \\cdot D_{i} - C_{i}.\n$$\nThe forum shopping decision rule that maximizes expected net recovery is therefore:\n$$\ni^{\\ast} = \\arg\\max_{i \\in \\{\\mathrm{A}, \\mathrm{B}, \\mathrm{C}\\}} \\left( p_{i} \\cdot q_{i} \\cdot D_{i} - C_{i} \\right).\n$$\n\nWe now apply this rule to the given jurisdictions.\n\nFor Jurisdiction $\\mathrm{A}$, we compute:\n$$\np_{\\mathrm{A}} \\cdot q_{\\mathrm{A}} \\cdot D_{\\mathrm{A}} = 0.92 \\cdot 0.40 \\cdot 2.4 = 0.92 \\cdot 0.96 = 0.8832,\n$$\nso\n$$\nE[R_{\\mathrm{A}}] = 0.8832 - 0.60 = 0.2832 \\text{ (million USD)}.\n$$\n\nFor Jurisdiction $\\mathrm{B}$, we compute:\n$$\np_{\\mathrm{B}} \\cdot q_{\\mathrm{B}} \\cdot D_{\\mathrm{B}} = 0.78 \\cdot 0.50 \\cdot 1.8 = 0.78 \\cdot 0.90 = 0.702,\n$$\nso\n$$\nE[R_{\\mathrm{B}}] = 0.702 - 0.40 = 0.302 \\text{ (million USD)}.\n$$\n\nFor Jurisdiction $\\mathrm{C}$, we compute:\n$$\np_{\\mathrm{C}} \\cdot q_{\\mathrm{C}} \\cdot D_{\\mathrm{C}} = 0.40 \\cdot 0.55 \\cdot 3.5 = 0.40 \\cdot 1.925 = 0.77,\n$$\nso\n$$\nE[R_{\\mathrm{C}}] = 0.77 - 0.90 = -0.13 \\text{ (million USD)}.\n$$\n\nComparing these expected net recoveries, we have:\n$$\nE[R_{\\mathrm{A}}] = 0.2832, \\quad E[R_{\\mathrm{B}}] = 0.302, \\quad E[R_{\\mathrm{C}}] = -0.13 \\text{ (million USD)}.\n$$\nThe optimal forum is Jurisdiction $\\mathrm{B}$, with the highest expected net recovery. The problem requests the optimal expected net recovery value, rounded to four significant figures and expressed in million United States dollars. Rounding $0.302$ to four significant figures yields $0.3020$ (the trailing zero indicates the fourth significant figure).\n\nTherefore, the optimal expected net recovery value is $0.3020$ million United States dollars.", "answer": "$$\\boxed{0.3020}$$", "id": "4475886"}]}